Associated Papers
Common gene mutations in 103 authenticated colorectal cancer cell lines.
Kranjec C et al.
Oncogenesis, 2026
41593049 (PubMed )
Supplement: 41389_2026_599_MOESM2_ESM.xlsx › Supplementary_Table_9
Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases.
Usui Y et al.
Blood Cancer Discovery, 2025
40525786 (PubMed )
Supplement: bcd-24-0355_table_s2_suppst2.xlsx › Sheet1
Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance.
Faulkner LG et al.
Cancer Investigation, 2025
39989311 (PubMed )
Supplement: supplement_1.pdf
DNA replication stress underpins the vulnerability to oxidative phosphorylation inhibition in colorectal cancer.
Zhao XH et al.
Cell Death & Disease, 2025
39809754 (PubMed )
Supplement: 41419_2025_7334_MOESM1_ESM.pdf
HDAC and MEK inhibition synergistically suppresses HOXC6 and enhances PD-1 blockade efficacy in BRAFV600E-mutant microsatellite stable colorectal cancer.
Sun Z et al.
Journal for Immunotherapy of Cancer, 2025
39800382 (PubMed )
Supplement: jitc-13-1-s001.pdf
RNA hybrid-capture next-generation sequencing has high sensitivity in identifying known and less characterized oncogenic and likely oncogenic NTRK fusions in a real-world standard-of-care setting.
Wallen ZD et al.
Frontiers in Genetics, 2025
40385986 (PubMed )
Supplement: Supplementaryfile1.xlsx › Supplementary_Table_3
Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer.
Kjeldsen MK et al.
Cancer Research Communications, 2024
39591206 (PubMed )
Supplement: crc-24-0294_supplementarygenetable_s1_suppst1.xlsx › SupplementaryGeneTableS1
Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib.
Aslan B et al.
Blood Advances, 2024
38968154 (PubMed )
Supplement: BLOODA_ADV-2023-012360-mmc1.pdf
Representing mutations for predicting cancer drug response.
Wall P et al.
Bioinformatics (oxford, England), 2024
Utilization of cytologic cell blocks for targeted sequencing of solid tumors.
Vormittag-Nocito E et al.
Cancer Medicine, 2023
36125633 (PubMed )
Supplement: CAM4-12-4042-s001.xlsx › Sheet1
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer.
Yuan D et al.
Investigational New Drugs, 2022
The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.
Deek MP et al.
European Urology, 2021
33419682 (PubMed )
Supplement: NIHMS1793749-supplement-20.xlsx › Sheet1
Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.
Watanabe T et al.
Journal of Ovarian Research, 2021
34615547 (PubMed )
Supplement: 13048_2021_876_MOESM1_ESM.xlsx › Sheet1
Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy.
Kim Y et al.
Cancer Cell International, 2021
33435996 (PubMed )
Supplement: 12935_2021_1761_MOESM1_ESM.docx
Identification of relevant genetic alterations in cancer using topological data analysis.
Rabadán R et al.
Nature Communications, 2020
32732999 (PubMed )
Supplement: 41467_2020_17659_MOESM3_ESM.xls › TableS1
Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S et al.
Oncotarget, 2016
27191893 (PubMed )
Supplement: oncotarget-07-48577-s002.xlsx › Sheet1
Analysis of TP53 mutation status in human cancer cell lines: a reassessment.
Leroy B et al.
Human Mutation, 2014
Select a paper to view details